Experts Urge Shift in Obesity Treatment and Long-Term GLP-1 Care

Leading medical experts emphasize that obesity is a complex chronic disease driven by biological factors rather than willpower, requiring long-term GLP-1 treatments and multidisciplinary care.

Experts Urge Shift in Obesity Treatment and Long-Term GLP-1 Care
Photo-illustration WireIsrael: AI Generated

Medical experts are calling for a fundamental shift in how obesity is perceived, emphasizing that the condition is a chronic disease rather than a failure of personal willpower. Speaking at a recent medical conference, leading endocrinologists highlighted that modern GLP-1 receptor agonist medications have transformed treatment approaches, though successful management requires comprehensive multi-disciplinary support rather than a quick fix.

Redefining Obesity as a Chronic Disease

Professor Dror Dicker, director of the Endocrinology, Diabetes, and Hypertension Institute at Tel Aviv Medical Center, stressed that obesity behaves similarly to other chronic illnesses such as diabetes or hypertension. The condition is associated with more than 220 long-term complications, encompassing respiratory, metabolic, and orthopedic disorders. Treating excess weight has never been a matter of willpower, noted medical professionals, comparing past misconceptions about obesity to historical views on ulcers, which were once blamed on psychological distress before being linked to bacteria.

Human biology actively resists sustained weight loss due to evolutionary survival mechanisms designed to prevent starvation. According to clinical data, among individuals with a body mass index exceeding 30, only one in twenty manages to lose 10 percent of their body weight and maintain that loss for a full year. Because the body establishes a biological set point governed by genetics and environment, dropping below that threshold triggers physiological defenses that drive weight back up.

The Role of GLP-1 Treatments and Multidisciplinary Care

Dr. Hadar Daskin-Biton, head of diabetes and endocrinology in the community division at Clalit Health Services, pointed out that modern pharmaceutical interventions offer a vital tool by quieting what patients describe as "food noise"—the constant mental preoccupation with meals. Beyond weight reduction, these medications deliver cardiovascular benefits, decrease liver fat, alleviate sleep apnea, and improve mobility, even for individuals who achieve modest weight loss.

Experts emphasized that pharmacological therapy must not be approached as a "set-and-forget" solution. Over 100,000 Clalit members currently receive these treatments through supplemental insurance plans, reflecting surging demand. However, proper administration requires coordinated care involving dietetics, physical activity guidance, and regular physician oversight. Gradual dosage escalation tailored to each patient helps mitigate gastrointestinal side effects such as nausea and diarrhea, while significantly improving long-term adherence compared to rapid dose increases.

Preserving Muscle Mass and Ensuring Persistence

Addressing concerns regarding muscle mass reduction, specialists explained that lean tissue loss accompanies any form of significant weight loss, including traditional diets and bariatric surgery. The priority remains functional strength, with clinical trials indicating that most patients report feeling physically stronger and more mobile. Nevertheless, physicians advise caution among elderly populations, recommending structured physical activity alongside pharmacotherapy to preserve muscle mass. Discontinuing treatment typically results in weight regain, reinforcing the consensus that obesity management requires lifelong medical balance and sustained behavioral support.

Related News